Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference

11/17/2021 | 08:31am EST

LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and Chief Executive Officer of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat hosted by Evercore on Tuesday, November 30th, 2021 at 1:50 PM EST.

Registration can be completed in advance at: https://wsw.com/webcast/evercore21/agen/2323050.

A replay will be available after the call on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.   

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its affiliate MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Agenus Inc.
Divya Vasudevan, PhD

Agenus Media Relations
Kimberly Ha
KKH Advisors

Primary Logo

ę GlobeNewswire 2021
All news about AGENUS INC.
01/06AGENUS INC : Change in Directors or Principal Officers (form 8-K)
01/06Agenus Inc. Announces Resignation of Jennifer Buell as President and Chief Operating Of..
01/05Agenus to Participate at Upcoming Investor Conferences
2021Agenus - Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (..
2021Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO)
2021Agenus Inc. Announces Publication of Results in the Journal of Clinical Oncology from a..
2021HC Wainwright Starts Agenus at Buy With $12 Price Target
2021Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
2021Agenus - Clinical Activity of AGEN1181 Demonstrated Across Nine Treatment Resistant Can..
2021Clinical Activity of AGEN1181 Demonstrated Across Nine Treatment-Resistant Cancers at S..
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Financials (USD)
Sales 2021 313 M - -
Net income 2021 6,25 M - -
Net Debt 2021 - - -
P/E ratio 2021 -71,7x
Yield 2021 -
Capitalization 688 M 688 M -
Capi. / Sales 2021 2,20x
Capi. / Sales 2022 10,3x
Nbr of Employees 359
Free-Float -
Duration : Period :
Agenus Inc. Technical Analysis Chart | AGEN | US00847G7051 | MarketScreener
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,69 $
Average target price 10,00 $
Spread / Average Target 272%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Wadih Jordan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.-16.46%691
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689